MethodSense Launches Elsa & AI Resource Center to Help Medical Device Companies Navigate the FDA’s AI Era
-
MethodSense Launches Elsa & AI Resource Center to Help Medical Device Companies Navigate the FDA’s AI Era
Morrisville, NC – July 11, 2025, MethodSense, a regulatory consulting and technology firm with more than 25 years of experience guiding medical device companies through the FDA and onto commercial markets, today announced the launch of its Elsa & AI Resource Center at MethodSense.com. This new resource hub provides critical guidance, tools, and expert insights…
-
Tech Innovator Richard Holcomb Joins MethodSense as Chief Growth Officer
Appointment strengthens MethodSense’s expansion strategy and LuminLogic platform leadership as the company accelerates into the AI-driven future of regulatory compliance… Morrisville, NC – July 02, 2025, MethodSense, a regulatory consulting firm and developer of the LuminLogic® compliance management platform, today announced the appointment of Richard Holcomb as its Chief Growth Officer (CGO). A distinguished entrepreneur,…
-
The FDA Just Went AI. Are You Ready?
Elsa Signals the Start of the FDA’s AI Era. Here’s What It Means for YouBy Rita King, CEO, MethodSense The FDA just dropped a game-changer: Elsa, its new generative AI tool. And it’s already transforming how medical device companies are evaluated and regulated. Elsa is actively supporting FDA reviews. At MethodSense, we have already seen…
-
Powered by LuminLogic
AI-enabled eQMS & Regulatory Compliance Platform MethodSense combines expert consulting with the power of LuminLogic®, our AI-enabled eQMS & Regulatory Compliance Platform. Developed through more than 25 years of regulatory, quality, and commercialization experience, LuminLogic transforms proven methodologies into connected workflows, intelligent automation, and real-time visibility that accelerate execution across the MedTech product lifecycle. Every…